Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 13, Issue 2, 2006, Pages 159-167

  Yoshida, Kenya ^a   Tomita, Yasuhiko ^a   Okuda, Yorihide ^a   Yamamoto, Shinji ^a   Enomoto, Hirayuki ^a   Uyama, Hirokazu ^a   Ito, Hiroaki ^a   Hoshida, Yoshihiko ^a   Aozasa, Katsuyuki ^a   Nagano, Hiroaki ^a   Sakon, Masato ^a   Kawase, Ichiro ^a   Monden, Morito ^a   Nakamura, Hideji ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Hepatoma derived growth factor; Prognosis; Recurrence

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; MESSENGER RNA;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION FUNCTION; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 31544442216     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.11.035     Document Type: Article

References (29)

1. Parkin DM, Muir CS. Cancer Incidence in Five Continents: Comparability and Quality of Data. Lyon: International Agency for Research on Cancer Scientific Publications, 1992; 45-173.
2. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229:790-9.
3. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995; 221:291-8.
4. Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998; 83:2302-11.
5. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63-70.
6. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527-36.
7. Ng IO. Prognostic significance of pathological and biological factors in hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13:666-70.
8. Nakamura H, Kambe H, Egawa T, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989; 183:273-84.
9. Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994; 269:25143-9.
10. Izumoto Y, Kuroda T, Harada H, Kishimoto T, Nakamura H. Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus. Biochem Biophys Res Commun 1997; 238:26-32.
11. Kishima Y, Yamamoto H, Izumoto Y, et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 2002; 277:10315-22.
12. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001; 276:37564-8.
13. Enomoto H, Yoshida K, Kishima Y, et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002; 36:1519-27.
14. Everett AD, Lobe DR. Matsumura ME, Nakamura H, McNamara CA. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000; 105:567-75.
15. Kishima Y, Yoshida K, Enomoto H, et al. Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepatogastroenterology 2002; 49:1639-44.
16. Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest 1998; 102: 1208-19.
17. Okuda Y, Nakamura H, Yoshida K, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 2003; 94:1034-41.
18. Yoshida K, Nakamura H, Okuda Y, et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 2003; 18:1293-301.
19. Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7:462-503.
20. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
21. Kaplan E, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53:457-81.
22. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
23. The Liver Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74:2772-80.
24. Fusenig NE, Breitkreutz D, Boukamp P, Tomakidi P, Stark HJ. Differentiation and tumor progression. Recent Results Cancer Res 1995; 139:1-19.
25. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22:172-8.
26. Sugihara S, Nakashima O, Kojiro M, Majima Y, Tanaka M, Tanikawa K. The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer 1992; 70:1488-92.
27. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29:688-96.
28. Morimitsu Y, Hsia CC, Kojiro M, Tabor E. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995; 26:1126-32.
29. Nart D, Arikan C, Akyildiz M, et al. Hepatocellular carcinoma in liver transplant era: a clinicopathologic analysis. Transplant Proc 2003; 35:2986-90.